Not medical advice. A record of published research and our assessments of it. The limits

Studies

Every study, review and regulatory document in the collection, newest first. Each links to a page with its population, findings, funding and original source.

01Find

Filter studies

Search titles and summaries

Population match

Topic

Drug

Design

Study tier

Outcome type

Direction

Explained by weight loss?

Industry funded

Peer reviewed

Published from year

Clear filters

4 studies · Download as JSON

Efficacy and safety of orforglipron 12 mg versus orforglipron 36 mg maintenance dose among patients with obesity with or without diabetes: a systematic review and comprehensive meta-analysisMeta-analysis · 2026 · Study tier 2 · Different population · Mixed · Unreviewed automatic assessment
Obstructive sleep apnea, GLP-1 receptor agonist pharmacotherapy, and the oral microbiome: competing biological influences and implications for oral health monitoringPharmacovigilance · 2026 · Study tier 4 · Different population · Harm direction · Unreviewed automatic assessment
Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic ReviewSystematic review · 2026 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetesRandomized trial · 2025 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment